ACA
MGRX icon

Ackerman Capital Advisors’s Mangoceuticals MGRX Stock Holding History

Ackerman Capital Advisors’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1K Hold
34,500
– – ﹤0.01% 120
2026
Q1 		$12.4K Hold
34,500
– – ﹤0.01% 115
2025
Q4 		$25.5K Hold
34,500
– – 0.01% 121
2025
Q3 		$75.6K Hold
34,500
– – 0.02% 116
2025
Q2 		$52.4K Hold
34,500
– – 0.01% 112
2025
Q1 		$67.3K Hold
34,500
– – 0.02% 108
2024
Q4 		$83.5K Sell
34,500
-23,724
-41% -$62.2K 0.02% 99
2024
Q3 		$206K Buy
+58,224
New +$275K 0.05% 92

Other funds holding MGRX

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
AA
ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return

Ackerman Capital Advisors's MGRX Position: Q2 2026 in Review

Ackerman Capital Advisors held its Mangoceuticals (MGRX) position steady in Q2 2026 at 34,500 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #120.

Ackerman Capital Advisors first reported a position in MGRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $206K in Q3 2024. 18 funds tracked by Wall St. Rank hold MGRX as of Q2 2026.

  • Ackerman Capital Advisors held 34,500 shares of Mangoceuticals worth $13.1K as of Q2 2026.
  • Ackerman Capital Advisors left its Mangoceuticals share count unchanged in Q2 2026.
  • Mangoceuticals made up ﹤0.01% of Ackerman Capital Advisors's portfolio in Q2 2026, its #120 holding.
  • Ackerman Capital Advisors first reported a position in Mangoceuticals in Q3 2024 and has held it in 8 quarters since.
  • Ackerman Capital Advisors's Mangoceuticals position peaked at $206K in Q3 2024.
  • 18 funds tracked by Wall St. Rank held Mangoceuticals as of Q2 2026.

Based on Ackerman Capital Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.